Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in NNOX.

← Back to Free Index

NNOX

Analysis as of: 2026-02-28

NANO-X IMAGING LTD

Nanox develops digital tomosynthesis imaging systems and sells attached cloud, AI imaging software, and teleradiology services to healthcare providers.

ai hardware healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Regulated upgrades seek a recurring imaging workflow flywheel

The 5-year upside depends on proving that deployments translate into sustained exam throughput and recurring services, not just regulatory wins. Financing capacity and unit economics are the main gates that determine whether the model scales or dilutes.

Analysis

Thesis

If Nanox turns regulatory-cleared, cloud-delivered upgrades (e.g., TAP2D) plus a smaller-footprint system into a repeatable “install + workflow + interpretation” motion, revenue can inflect non-linearly as deployments convert into durable exam throughput and recurring services—while a regulated upgrade channel protects pricing better than pure imaging AI.

Last Economy Alignment

Cheap AI makes image interpretation and standalone imaging AI easier to copy, but regulated hardware + a controlled, remotely upgradable pipeline can anchor trust and recurring workflow revenue—if they reach scale before incumbents out-bundle them.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

7.6x (from 5 most recent analyses)

Reasoning

The upside is a phase change from “units placed” to “exams flowing” where each deployed system becomes a recurring revenue node (upgrades + workflow + interpretation), supported by the recent stepwise regulatory progress and an operating model that can improve revenue per site without new hardware cycles. The downside is that hospitals’ workflow inertia and incumbent OEM bundling cap adoption, keeping Nanox sub-scale and forcing repeated equity raises. This snapshot assumes Nanox earns a modest but real share of a large imaging + interpretation spend pool, and is valued like an emerging, mixed hardware/services platform rather than a premium software pure-play.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

Two gates dominate 2026–2031 outcomes: (1) liquidity/financing (avoiding forced, repeated dilution while funding deployments and service capacity) and (2) conversion of placements into durable clinical throughput with improving margins. Even with regulatory progress, incumbent imaging OEM distribution and workflow inertia can cap adoption unless Nanox shows a repeatable “install → exams → recurring revenue” engine.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No new SEC-filed financial results since the Q3-2025 release dated November 20, 2025; next results are still expected around late March/early April 2026 per market calendars.
The February 17, 2026 update shifted near-term attention to March 4–8, 2026 (ECR 2026) demos/data, a potential sentiment catalyst but not yet a monetization proof point.
Share price remained in the low-$2 range in the week ending February 27, 2026, implying the market is still pricing high execution + financing risk.

Forecast update

Slightly more conservative on terminal value capture given still-weak gross margin optics and ongoing financing overhang; core thesis mechanics unchanged.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.29

They control regulated imaging hardware and a vendor-controlled, remotely upgradable pipeline that can keep adding value to each installed system over time. The risk is that cheap AI and incumbent OEM bundling commoditize the workflow layer before Nanox reaches enough deployed scale to matter.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$7.00

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research